Eli Lilly has appointed Lucas Montarce as its new Chief Financial Officer, following the departure of former CFO Anat Ashkenazi, who left to join Alphabet. Montarce has been a company insider since 2001 and has held several leadership roles within Lilly. His appointment comes as the pharmaceutical giant invests billions to boost manufacturing capacity for its diabetes and weight loss drugs, Mounjaro and Zepbound. These drugs are expected to drive a weight loss drug market that could reach $150 billion within the next decade.
